Search Results

Every time a problem arises, we trace it back to its root cause, implementing changes that prevent its

Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already This is where funders, peers, and biotech scouts are watching. Access peer insights on allosteric modulators and biased ligands.

And once you make that shift, you’ll never go back.

It was mostly just because, I need to be back in the lab.”

With over 21,000 views  and 7,785 downloads  from Volume I, the Signal Transduction  Research Topic is back

Our website is updated as we confirm speakers so please check back often.

From outside to inside and back again: the lysophosphatidic acid-CCN axis in signal transduction.

pathophysiology and treatment of CNS disorders GPCRs in Oncology and Immunology From outside to inside and back

Welcome back GPCR fans, The pace of GPCR innovation is accelerating at a rate that can be difficult to

a cold email from a biologist he’d never met, asking if he could synthesize a molecule “when you’re back

Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors Industry News Sosei Heptares to take back

with Multispan Cell Engineering and Assay Services $3bn sales potential for drug Sosei Heptares wants back

Welcome back GPCR lovers, In pharmacology, the wrong interpretation of antagonist behavior can derail Avoid the professional threat of falling behind your peers by accessing the same insights that are driving

Unexpected outcomes typically trace back to a single issue: transferring assumptions from idealized models Kenakin demonstrates how premature stopping mis-ranks compounds, particularly when tracer and displacer

Warm greetings and a resounding welcome back to our GPCR Weekly Newsletter, rejuvenated after the festive

binds to CCR1, CCR3 and CCR5, and induces different patterns of receptor recycling where CCR5 recycles back

with AEF0217 in young adults with Down syndrome Novartis pays Schrödinger $150M, bets billions on the back

We're zooming back to the future of GPCR discoveries.

We're excited to be back and share our weekly newsletter!

👉 Most founders look back at the end of the year and try to make sense of the results.

The excitement I felt when I first attended back in Boston is the same one I feel now that I am the organizer

Structure: the development of algorithms such DeepMind’s Alphafold2 (Jumper et al., 2021) and RoseTTAFold (Baek

donors, since they have extended fluorescence duration, enable delayed emission readings, have narrow bands